Physiologic Estrogen/progesterone

Small molecule

Physiologic Estrogen/progesterone is one of 40 small molecule programs targeting Anorexia Nervosa. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anorexia NervosaActive, not recruiting

Anorexia NervosaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Anorexia Nervosa

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

6 2

Abilify

Otsuka

Approved

2 3

Risperdal

WWim Janssens

Approved

1 4

Prometrium

Pitocin

Remeron

Marinol

Alnylam Pharmaceuticals

Phase 3

1 8

Zometa

Pfizer

Phase 3

1 9

Prolia

Amgen

Phase 3

1 10

Aricept

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anorexia Nervosa1 trial

Effects of Anorexia Nervosa on Bone Mass in Adolescents

Completed·MMassachusetts General Hospital·Phase 2/3·NCT00088153·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Physiologic Estrogen/progesterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Physiologic Estrogen/progesterone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Physiologic Estrogen/progesterone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMassachusetts General Hospital

Physiologic Estrogen/progesterone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anorexia Nervosa1 trial

References

Drug Info

Quick Facts

Related News